Related Research Articles
A zinc finger is a small protein structural motif that is characterized by the coordination of one or more zinc ions (Zn2+) which stabilizes the fold. It was originally coined to describe the finger-like appearance of a hypothesized structure from the African clawed frog (Xenopus laevis) transcription factor IIIA. However, it has been found to encompass a wide variety of differing protein structures in eukaryotic cells. Xenopus laevis TFIIIA was originally demonstrated to contain zinc and require the metal for function in 1983, the first such reported zinc requirement for a gene regulatory protein followed soon thereafter by the Krüppel factor in Drosophila. It often appears as a metal-binding domain in multi-domain proteins.
Zinc-finger nucleases (ZFNs) are artificial restriction enzymes generated by fusing a zinc finger DNA-binding domain to a DNA-cleavage domain. Zinc finger domains can be engineered to target specific desired DNA sequences and this enables zinc-finger nucleases to target unique sequences within complex genomes. By taking advantage of endogenous DNA repair machinery, these reagents can be used to precisely alter the genomes of higher organisms. Alongside CRISPR/Cas9 and TALEN, ZFN is a prominent tool in the field of genome editing.
Charles Thomas Caskey, also known as C. Thomas Caskey, was an American internist who has been a medical Geneticist and biomedical researcher and entrepreneur. He was a Professor of Molecular and Human Genetics at Baylor College of Medicine, and served as editor of the Annual Review of Medicine from 2001 to 2019. He was a member of the editorial boards of the Proceedings of the National Academy of Sciences, Science, the Encyclopedia of Molecular Medicine and numerous other medical and scientific journals.
Johan Georg Harmenberg Åkerman is a Swedish Olympic and world champion épée fencer.
Zinc finger protein chimera are chimeric proteins composed of a DNA-binding zinc finger protein domain and another domain through which the protein exerts its effect. The effector domain may be a transcriptional activator (A) or repressor (R), a methylation domain (M) or a nuclease (N).
The National Organization for Rare Disorders (NORD) is a nonprofit organization, based in Connecticut, aiming to provide support for individuals with rare diseases by advocating and funding research, education, and networking among service providers. It was founded in 1983 by Abbey Meyers, along with individuals and rare diseases leaders of rare disease support groups, and it is a 501(c)(3) tax exempt organization.
Acorda Therapeutics, Inc. is an American biotechnology company based in Pearl River, New York. The company develops therapies that improve neurological function in people with Parkinson's disease, multiple sclerosis and other neurological disorders. Acorda Therapeutics manufactures and markets the drugs Inbrija and Ampyra (dalfampridine) in the United States.
Transcription activator-like effector nucleases (TALEN) are restriction enzymes that can be engineered to cut specific sequences of DNA. They are made by fusing a TAL effector DNA-binding domain to a DNA cleavage domain. Transcription activator-like effectors (TALEs) can be engineered to bind to practically any desired DNA sequence, so when combined with a nuclease, DNA can be cut at specific locations. The restriction enzymes can be introduced into cells, for use in gene editing or for genome editing in situ, a technique known as genome editing with engineered nucleases. Alongside zinc finger nucleases and CRISPR/Cas9, TALEN is a prominent tool in the field of genome editing.
Brett P. Giroir is an American pediatrician. He was formerly the U.S. assistant secretary for health, a four-star admiral in the U.S. Public Health Service Commissioned Corps and an acting Food and Drug Administration commissioner.
Genome editing, or genome engineering, or gene editing, is a type of genetic engineering in which DNA is inserted, deleted, modified or replaced in the genome of a living organism. Unlike early genetic engineering techniques that randomly inserts genetic material into a host genome, genome editing targets the insertions to site-specific locations. The basic mechanism involved in genetic manipulations through programmable nucleases is the recognition of target genomic loci and binding of effector DNA-binding domain (DBD), double-strand breaks (DSBs) in target DNA by the restriction endonucleases, and the repair of DSBs through homology-directed recombination (HDR) or non-homologous end joining (NHEJ).
Arie S. Belldegrun, FACS, is an Israeli-American urologic oncologist, billionaire businessman and investor.
Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".
Carl O. Pabo is a biophysicist. He is the founder and president of Humanity 2050, a nonprofit institute.
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.
Since antiretroviral therapy requires a lifelong treatment regimen, research to find more permanent cures for HIV infection is currently underway. It is possible to synthesize zinc finger nucleotides with zinc finger components that selectively bind to specific portions of DNA. Conceptually, targeting and editing could focus on host cellular co-receptors for HIV or on proviral HIV DNA.
Sangamo Therapeutics, Inc. is an American biotechnology company based in Brisbane, California. It applies cell and gene therapy to combat haemophilia and other genetic diseases.
Howard David Krein is an American otolaryngologist, plastic surgeon, and business executive. He is the husband of Ashley Biden, the daughter of U.S. president Joe Biden. He is a professor of otolaryngology at Thomas Jefferson University and is a founding partner and co-director of Thomas Jefferson University Hospital's Facial Aesthetic and Reconstructive Center. Krein is the chief medical officer at StartUp Health, a venture capital and health technology firm. He served on the Biden Cancer Initiative's board of directors from 2017 to 2019. Krein advised the Joe Biden 2020 presidential campaign on its COVID-19 pandemic response in an unofficial role.
Alan Edward Smith is a British geneticist who was Chief Scientific Officer of Genzyme from 1996 to 2011.
Fyodor Dmitriyevich Urnov is Russian-born biomedical researcher and who has played a leading role in the field of genome editing. He is a Professor of Genetics, Genomics, and Development at the University of California, Berkeley and Director of the Center for Translational Genomics at the university's Innovative Genomics Institute. In 2005 Urnov and his colleagues coined the term "genome editing" and demonstrated the first use of ZFNs to edit DNA in human cells. Urnov is considered a pioneering figure in the field of genome editing and his work has been cited widely.
N. Anthony Coles is an American physician, biotechnology entrepreneur, and pharmaceutical leader. Since 2018, Coles has served as chair of the board of directors for Cerevel Therapeutics.
References
- ↑ "Sana Biotechnology Strengthens Senior Research Leadership Team with Ed Rebar, Ph.D. and Terry Fry, M.D." PR Newswire. Retrieved May 26, 2023.
- ↑ Rebar, Edward John (1997). Selection studies of zinc finger-DNA recognition (Thesis). OCLC 37525775.
- 1 2 "Sangamo Therapeutics appoints Edward Rebar as senior vice president". Post Online Media. Richmond, California. July 16, 2018. Retrieved October 1, 2018.
- ↑ Hale, Conor (July 20, 2018). "Chutes & Ladders: Sangamo loses another top executive". FierceBiotech. Retrieved February 11, 2019.
- ↑ "Sana Biotechnology Strengthens Senior Research Leadership Team with Ed Rebar, Ph.D. and Terry Fry, M.D." PR Newswire. Retrieved May 26, 2023.
| International | |
|---|---|
| National | |
| Academics | |
